Hypomethylating Agents in Oncohematology
The review describes epigenetic processes, including methylation of nuclear and mitochondrial DNA, as well as RNA. It dwells on mechanisms of demethylation and corresponding medicinal products. It presents detailed information on results of numerous large randomized studies intended to evaluate hypo...
Main Authors: | , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Practical Medicine Publishing House
2016-10-01
|
Series: | Kliničeskaâ onkogematologiâ |
Subjects: | |
Online Access: | http://bloodjournal.ru/en/hypomethylating-agents-in-oncohematology/ |
id |
doaj-8120b36f1ca34a83ba692c788b4d69ec |
---|---|
record_format |
Article |
spelling |
doaj-8120b36f1ca34a83ba692c788b4d69ec2020-11-24T23:31:40ZrusPractical Medicine Publishing HouseKliničeskaâ onkogematologiâ1997-69332500-21392016-10-019436938210.21320/2500-2139-2016-9-4-369-382Hypomethylating Agents in OncohematologyAD Shirin, 0OYu Baranova1NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478The review describes epigenetic processes, including methylation of nuclear and mitochondrial DNA, as well as RNA. It dwells on mechanisms of demethylation and corresponding medicinal products. It presents detailed information on results of numerous large randomized studies intended to evaluate hypomethylating agents (azanucleosides). Special attention is paid to outcomes of azanucleoside therapy in patients with acute myeloid leukemias. The article describes several prognostic systems and treatment algorithms for myelodysplastic syndromes. Two azanucleosides have been approved in Russia to date: azacitidine (for SQ administration) and decitabine (for IV administration). International authors analyze the experience in oral and subcutaneous administration of decitabine. However, the problem of off-label use of hypomethylating agents is still open. The review gives a brief description of ongoing clinical trials with azanucleosides.http://bloodjournal.ru/en/hypomethylating-agents-in-oncohematology/epigeneticsacute myeloid leukemiasmyelodysplastic syndromesazacitidinedecitabinehypomethylating agentsazanucleosides |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
AD Shirin, OYu Baranova |
spellingShingle |
AD Shirin, OYu Baranova Hypomethylating Agents in Oncohematology Kliničeskaâ onkogematologiâ epigenetics acute myeloid leukemias myelodysplastic syndromes azacitidine decitabine hypomethylating agents azanucleosides |
author_facet |
AD Shirin, OYu Baranova |
author_sort |
AD Shirin, |
title |
Hypomethylating Agents in Oncohematology |
title_short |
Hypomethylating Agents in Oncohematology |
title_full |
Hypomethylating Agents in Oncohematology |
title_fullStr |
Hypomethylating Agents in Oncohematology |
title_full_unstemmed |
Hypomethylating Agents in Oncohematology |
title_sort |
hypomethylating agents in oncohematology |
publisher |
Practical Medicine Publishing House |
series |
Kliničeskaâ onkogematologiâ |
issn |
1997-6933 2500-2139 |
publishDate |
2016-10-01 |
description |
The review describes epigenetic processes, including methylation of nuclear and mitochondrial DNA, as well as RNA. It dwells on mechanisms of demethylation and corresponding medicinal products. It presents detailed information on results of numerous large randomized studies intended to evaluate hypomethylating agents (azanucleosides). Special attention is paid to outcomes of azanucleoside therapy in patients with acute myeloid leukemias. The article describes several prognostic systems and treatment algorithms for myelodysplastic syndromes. Two azanucleosides have been approved in Russia to date: azacitidine (for SQ administration) and decitabine (for IV administration). International authors analyze the experience in oral and subcutaneous administration of decitabine. However, the problem of off-label use of hypomethylating agents is still open. The review gives a brief description of ongoing clinical trials with azanucleosides. |
topic |
epigenetics acute myeloid leukemias myelodysplastic syndromes azacitidine decitabine hypomethylating agents azanucleosides |
url |
http://bloodjournal.ru/en/hypomethylating-agents-in-oncohematology/ |
work_keys_str_mv |
AT adshirin hypomethylatingagentsinoncohematology AT oyubaranova hypomethylatingagentsinoncohematology |
_version_ |
1725536704138313728 |